Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.18
AMEX:ADK's Cash-to-Debt is ranked lower than
95% of the 257 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 0.40 vs. AMEX:ADK: 0.18 )
Ranked among companies with meaningful Cash-to-Debt only.
AMEX:ADK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.09 Max: N/A
Current: 0.18
Equity-to-Asset -0.32
AMEX:ADK's Equity-to-Asset is ranked lower than
97% of the 253 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 0.47 vs. AMEX:ADK: -0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
AMEX:ADK' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.32  Med: 0.11 Max: 0.26
Current: -0.32
-0.32
0.26
Interest Coverage 0.62
AMEX:ADK's Interest Coverage is ranked lower than
100% of the 216 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 8.17 vs. AMEX:ADK: 0.62 )
Ranked among companies with meaningful Interest Coverage only.
AMEX:ADK' s Interest Coverage Range Over the Past 10 Years
Min: 0.01  Med: 0.26 Max: 1.47
Current: 0.62
0.01
1.47
Piotroski F-Score: 4
Altman Z-Score: -0.56
Beneish M-Score: -2.99
WACC vs ROIC
7.65%
7.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % 15.56
AMEX:ADK's Operating Margin % is ranked lower than
73% of the 255 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 7.71 vs. AMEX:ADK: 15.56 )
Ranked among companies with meaningful Operating Margin % only.
AMEX:ADK' s Operating Margin % Range Over the Past 10 Years
Min: -727.76  Med: 0.43 Max: 15.56
Current: 15.56
-727.76
15.56
Net Margin % -27.30
AMEX:ADK's Net Margin % is ranked lower than
96% of the 256 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 4.84 vs. AMEX:ADK: -27.30 )
Ranked among companies with meaningful Net Margin % only.
AMEX:ADK' s Net Margin % Range Over the Past 10 Years
Min: -408.99  Med: -4.93 Max: 1.65
Current: -27.3
-408.99
1.65
ROA % -4.90
AMEX:ADK's ROA % is ranked lower than
88% of the 259 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 4.66 vs. AMEX:ADK: -4.90 )
Ranked among companies with meaningful ROA % only.
AMEX:ADK' s ROA % Range Over the Past 10 Years
Min: -12.4  Med: -4.97 Max: 1.54
Current: -4.9
-12.4
1.54
ROC (Joel Greenblatt) % 3.96
AMEX:ADK's ROC (Joel Greenblatt) % is ranked lower than
82% of the 257 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 21.13 vs. AMEX:ADK: 3.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMEX:ADK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -17.98  Med: 1.59 Max: 10.43
Current: 3.96
-17.98
10.43
3-Year Revenue Growth Rate -51.90
AMEX:ADK's 3-Year Revenue Growth Rate is ranked lower than
98% of the 183 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 8.50 vs. AMEX:ADK: -51.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMEX:ADK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -75.9  Med: -15.8 Max: 38.5
Current: -51.9
-75.9
38.5
3-Year EBITDA Growth Rate 11.00
AMEX:ADK's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 161 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 8.10 vs. AMEX:ADK: 11.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AMEX:ADK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5 Max: 11.8
Current: 11
0
11.8
3-Year EPS without NRI Growth Rate -56.70
AMEX:ADK's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 139 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 8.40 vs. AMEX:ADK: -56.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AMEX:ADK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -56.7  Med: 26 Max: 178.9
Current: -56.7
-56.7
178.9
GuruFocus has detected 2 Warning Signs with AdCare Health Systems Inc $AMEX:ADK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMEX:ADK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ADK Guru Trades in Q1 2016

Jim Simons 259,700 sh (+4.30%)
Mario Gabelli 153,933 sh (unchged)
» More
Q2 2016

ADK Guru Trades in Q2 2016

Mario Gabelli 162,668 sh (+5.67%)
Jim Simons 263,000 sh (+1.27%)
» More
Q3 2016

ADK Guru Trades in Q3 2016

Mario Gabelli 176,561 sh (+8.54%)
Jim Simons 253,700 sh (-3.54%)
» More
Q4 2016

ADK Guru Trades in Q4 2016

Jim Simons 254,600 sh (+0.35%)
Mario Gabelli 151,423 sh (-14.24%)
» More
» Details

Insider Trades

Latest Guru Trades with ADK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of AdCare Health Systems Inc

SymbolPriceYieldDescription
ADK.PRA22.5112.0810 7/8 % Cum Red Pfd Shs Series -A-

Business Description

Industry: Health Care Providers » Long-Term Care Facilities    NAICS: 621610    SIC: 8051
Compare:OTCPK:FUTU, NAS:DVCR, NAS:FVE, NYSE:GEN, NYSE:CSU, OTCPK:LWSCF, OTCPK:EXETF, NYSE:CIVI, NYSE:KND, NAS:ENSG, AMEX:NHC, OTCPK:CWSRF, NYSE:BKD, OTCPK:RHCGF, OTCPK:ORPEF » details
Traded in other countries:AH3.Germany,
Headquarter Location:USA
AdCare Health Systems Inc, through its subsidiaries is a self-managed real estate investment company that invests in real estate purposed for long-term care and senior living.

AdCare Health Systems Inc was incorporated in Ohio on August 14, 1991, under the name Passport Retirement, Inc. In 1995, the Company acquired substantially all of the assets and liabilities of AdCare Health Systems, Inc. and changed its name to AdCare Health Systems, Inc. On December 12, 2013, AdCare changed its state of incorporation from the State of Ohio to the State of Georgia. The Company through its subsidiaries is a self-managed real estate investment company that invests in real estate purposed for long-term care and senior living. Its business consists of leasing and subleasing such facilities to third-party tenants, which operate the facilities. The Company provides healthcare and related services to patients and residents, including skilled nursing and assisted living services, social services, various therapy services, and other rehabilitative and healthcare services for both long-term and short-stay patients and residents. The skilled nursing and assisted living facilities provide services to individuals needing long-term care in a nursing home or assisted living setting and provide management of those facilities. Through its subsidiaries, the Company provides a full complement of administrative services as well as consultative services that permit its local facility leadership teams to focus on the delivery of healthcare services. It also provides these services to unaffiliated third party long-term care operators and/or owners with whom it enters into management contracts. The Company currently provides these services to two unaffiliated facility owners. Its competitors include assisted living communities and other retirement facilities and communities, home health care agencies, nursing homes and convalescent centers, some of which operate on a not-for-profit or charitable basis. The health care industry is subject to numerous laws and regulations of federal, state and local governments.

Top Ranked Articles about AdCare Health Systems Inc

DIAGNOS Announces Operational Update of a Contract in India Valued at Up to $1.3M

BROSSARD, QUEBEC--(Marketwired - Jul 5, 2016) - Diagnos Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces today that it has successfully expanded its healthcare operations to three additional cities in India through its subsidiary, Diagnos Healthcare India Pvt. Ltd. The expansion agreement, announced on September 23rd, 2015, valued at up to $1.3M as per our estimated level of transactions, is being executed with a global pharmaceutical partner. Our operations in India now include a total of four mobile screening units, one in each of the following cities: Mumbai, Delhi, Chennai and Kolkata. For each of the cities, DIAGNOS provides a complete screening solution comprised of project managers, technicians, image interpretation services, branded vans and drivers, the CARA telemedicine platform, fundus cameras and accessories. "Since our first announcement of the project in 2013 we have screened thousands of patients in Mumbai and the surrounding area. Our client, along with patients and the clinics used as screening locations, have responded extremely positively to our screening services and we have seen 300% growth in patient volume since February of this year and an average of 1,400 patients per month. As a result of the success of the first screening unit, the new screening units function exactly the same way as the original one in Mumbai. We are excited to have expanded to other cities in India and look forward to continuing to grow in the country," said André Larente, DIAGNOS' President. About DIAGNOS Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources. About CARA
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union. Forward-looking information
This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these

statements. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information, please contact DIAGNOS, visit our website at www.diagnos.com, or visit the SEDAR website at www.sedar.com.





Andre Larente
President
(450) 678-8882, ext. 224




Read more...
DIAGNOS Announces Major Strategic Alliance in Latin America for a Contract of $1.38 M USD

BROSSARD, QUEBEC--(Marketwired - Jun 8, 2016) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), an innovative leader in healthcare technical services, including screening software and algorithm development, data analysis, and image processing, announces today a contract award for a strategic initiative in Latin America to screen a large population of diabetics by December 31, 2016. Under the final agreement, it is expected that DIAGNOS will receive a 40% deposit on the total amount and a monthly payment until December 31, 2016. DIAGNOS is working closely with the customer to identify the requirements for an additional two years of services. According to the International Diabetes Federation, this country, ranked 6th worldwide in number of people with diabetes, second in adult obesity, and first in child obesity, is taking the lead to reverse these unfavorable health trends by investing in prevention and education. In the last 20 years, the client has spent more than US$1.2 billion treating complications from diabetes which could have been avoided by implementing wellness programs. Blindness is one major complication that has a huge impact on our families and society. The objective is now to unburden the economic load by preventing up to 85% of blindness cases and delivering an accessible service of the highest quality. "Our commitment is to assist the National Diabetes Program via a mass screening project aimed at reducing the cost of diabetes and preventing vision loss in its population. After four years of experience deploying screening projects in many countries including India, UAE, Algeria, Poland, Canada, USA, Colombia, Mexico, we're highly committed to adding value to this program by offering comprehensive services. The uniqueness the DIAGNOS technology platform "CARA" (Computer Assisted Retinal Analysis) in terms of image processing and enhancement enables for faster referral to specialists," said Mr. André Larente, President of DIAGNOS. About DIAGNOS
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources. About CARA
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union. Forward-looking information
This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these

statements. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.





Andre Larente, President
1-877-678-8882 or (450) 678-8882, ext.: 224
[email protected]




Read more...
DIAGNOS Announces Short Term Financing

BROSSARD, QUEBEC--(Marketwired - Jun 7, 2016) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces $150,000 financing in the form of short term debt and bonus share warrants. DIAGNOS and an arm's length person (the "Lender") have entered into a loan agreement for a principal amount of $150,000 in the form of an unsecured and non-convertible loan, bearing interest at twelve percent (12%) per year (the "Loan"), with a term of up to one year. Interest is payable semi-annually in equal installments. As a loan bonus, the Corporation is granting the Lender 1,250,000 non-transferable share warrants (each a "Warrant") enabling its holder to purchase 1,250,000 shares of the Corporation at a price of $0.06 per share for a period of twelve months (the "Loan Bonus"). The loan proceeds will be used to fund operating expenses and development expenses related to the products of the Corporation. The Warrants and underlying common shares are subject to a four-month hold period from issuance date of the Warrants. The Loan Bonus remains subject to the final approval of the TSX Venture Exchange. All monies quoted in this press release were stated and paid in lawful money of Canada, unless otherwise specified. About DIAGNOS DIAGNOS is a publicly-traded Canadian corporation with a mission to improve the quality of patients' lives and minimize the economic burden of vision loss. Computer Assisted Retinal Analysis (CARA) is the Company's proprietary tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, the U.S. Food and Drug Administration, and the European Union. Forward-looking information
This document contains forward-looking information that involves risks and uncertainties, including without limitation, statements pertaining to the Private Placement and its use of proceeds. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. Unless required under law, DIAGNOS will not update this forward-looking information to reflect new events or circumstances Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.





Andre Larente
President
Telephone: 1-877-678-8882 or (450) 678-8882, ext.: 224




Read more...
DIAGNOS Announces Changes to its Board of Directors

BROSSARD, QUEBEC--(Marketwired - May 20, 2016) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, is pleased to announce, effective immediately, the appointment of Mr. Tristam Coffin and Mr. Jean-Yves Thérien as directors of the Corporation. Mr. Coffin is highly respected in the eye care field, with a weld of experience. Mr. Coffin is the owner of one of Canada's most prestigious optical centres in Montreal. "I am excited to take an active role in developing the strategy and continued growth in sales derived from the Corporation's innovative proprietary software platform to assist eye specialists in the detection of diabetic retinopathy," said Mr. Coffin. Mr. Jean-Yves Thérien currently serves as Vice President of Business Development for Nippon Dragon Resources Inc., a TSX venture exchange company in the exploration and development stage and previous to that he served as a financial advisor at Laurentian Bank for over 13 years. Mr. Thérien has a Bachelor in business administration with a specialization in finance. These appointments follow the resignation of Mr. Michael Singer, effective immediately, and Mr. Lloyd M. Segal, effective June 1st, 2016. Lloyd will end his nearly two-year tenure with DIAGNOS after working with the company to develop its go-to-market strategy, expanding the global reach of DIAGNOS' CARA product, and working with management to develop a plan to ensure the sustainable growth of the company. He noted that, "DIAGNOS is well-positioned, with the right technology, for the early-diagnosis and treatment of diabetic retinopathy patients across the globe." "I take this opportunity to thank Michael and Lloyd for their dedication and service to DIAGNOS shareholders," said Mr. André Larente, President of Diagnos. Mr. Philip Renaud will assume the role of chairman of the board. About DIAGNOS DIAGNOS is a publicly-traded Canadian corporation with a mission to improve the quality of patients' lives and minimize the economic burden of vision loss. Computer Assisted Retinal Analysis (CARA) is the Company's proprietary tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, the U.S. Food and Drug Administration, and the European Union. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.





DIAGNOS
Andre Larente
President
1-877-678-8882 or (450) 678-8882, ext.: 224




Read more...
DIAGNOS Announces an Update following Closing of Private Placement

BROSSARD, QUEBEC--(Marketwired - May 18, 2016) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces an update following the closing of a non-brokered private placement ("Private Placement") previously announced on May 3rd, 2016. The Private Placement now consists of 93 units for an aggregate value of $930,000, an increase of one unit and $10,000 over the amount of $920,000 previously announced on May 3rd, 2016. This update to the Private Placement is subject to final receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange, as well as the execution of formal documentation. All monies quoted in this press release shall be stated and paid in lawful money of Canada. About DIAGNOS DIAGNOS is a publicly-traded Canadian corporation with a mission to improve the quality of patients' lives and minimize the economic burden of vision loss. Computer Assisted Retinal Analysis (CARA) is the Company's proprietary tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, the U.S. Food and Drug Administration, and the European Union. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.





Marc-Andre Massue, CFO
DIAGNOS
1-877-678-8882 or (450) 678-8882, ext.: 235




Read more...
DIAGNOS Announces Closing of Private Placement

BROSSARD, QUEBEC--(Marketwired - May 3, 2016) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces the closing of a non-brokered private placement ("Private Placement") previously announced on April 7, 2016. The Private Placement consists of 92 units (each a "Unit") for an aggregate value of $920,000. Each Unit consists of:

One Secured Convertible Debenture ("Debenture"), $10,000 principal amount, 1-Year Term, 12% Annual Interest, and


50,000 Stock Warrants (each a "Warrant') entitling the holder to purchase one Common Share ("Share") per Warrant at a price of $0.06 per Share for a period of one year from the date of issuance.

At the sole option of the holders of the Debentures, the principal amount of the Debentures may be converted at any time during the 1-year term, in whole or in part, into common shares of the Corporation at a price of $0.06 per common share. Any accrued interest on the principal, at time of conversion, is immediately payable in cash. There are no cash proceeds as the Debentures and Warrants are issued solely in settlement of outstanding debt pertaining to Unsecured Convertible and Redeemable Promissory Notes ("Notes"), bearing interest at 10%, with a conversion and redemption price of $0.16, issued between March 31, 2014 and May 2, 2014. The Corporation will make a special payment, in the form of interest at the annual rate of 12%, to compensate the holders of the Debentures and Warrants for the number of accrued days between the expiry date of the initial Notes and the date of this announcement. The Corporation has retained the services of Echelon Wealth Partners (formerly Dundee Goodman Private Wealth, a division of Dundee Securities Ltd.) ("Echelon"), to act as a referral agent in connection with the Private Placement. As per the engagement agreement, Echelon is entitled to receive a commission in cash of $20,000. Shares underlying the Debentures and Warrants will be subject to a statutory four-month hold period from the closing date. This Private Placement is subject to final receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange, as well as the execution of formal documentation. All monies quoted in this press release shall be stated and paid in lawful money of Canada. About DIAGNOS DIAGNOS is a publicly-traded Canadian corporation with a mission to improve the quality of patients' lives and minimize the economic burden of vision loss. Computer Assisted Retinal Analysis (CARA) is the Company's proprietary tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, the U.S. Food and Drug Administration, and the European Union. Forward-looking information This document contains forward-looking information that involves risks and uncertainties, including without limitation, statements pertaining to the Private Placement and its use of proceeds. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. Unless required under law, DIAGNOS will not update this forward-looking information to reflect new events or circumstances Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.





DIAGNOS Inc.
Andre Larente
President
1-877-678-8882 or (450) 678-8882, ext.: 224




Read more...

Ratios

vs
industry
vs
history
PS Ratio 0.76
ADK's PS Ratio is ranked higher than
71% of the 238 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 1.57 vs. ADK: 0.76 )
Ranked among companies with meaningful PS Ratio only.
ADK' s PS Ratio Range Over the Past 10 Years
Min: 0.1  Med: 0.37 Max: 4.92
Current: 0.76
0.1
4.92
EV-to-EBIT 20.38
ADK's EV-to-EBIT is ranked lower than
98% of the 292 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 18.39 vs. ADK: 20.38 )
Ranked among companies with meaningful EV-to-EBIT only.
ADK' s EV-to-EBIT Range Over the Past 10 Years
Min: -747.2  Med: 24.6 Max: 180.1
Current: 20.38
-747.2
180.1
EV-to-EBITDA 9.08
ADK's EV-to-EBITDA is ranked lower than
60% of the 306 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 13.46 vs. ADK: 9.08 )
Ranked among companies with meaningful EV-to-EBITDA only.
ADK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -571.2  Med: 18 Max: 92.1
Current: 9.08
-571.2
92.1
Current Ratio 0.81
ADK's Current Ratio is ranked lower than
70% of the 244 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 1.30 vs. ADK: 0.81 )
Ranked among companies with meaningful Current Ratio only.
ADK' s Current Ratio Range Over the Past 10 Years
Min: 0.39  Med: 0.84 Max: 1.59
Current: 0.81
0.39
1.59
Quick Ratio 0.81
ADK's Quick Ratio is ranked lower than
64% of the 244 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 1.18 vs. ADK: 0.81 )
Ranked among companies with meaningful Quick Ratio only.
ADK' s Quick Ratio Range Over the Past 10 Years
Min: 0.39  Med: 0.84 Max: 1.59
Current: 0.81
0.39
1.59
Days Sales Outstanding 32.43
ADK's Days Sales Outstanding is ranked lower than
53% of the 209 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 40.40 vs. ADK: 32.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
ADK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.1  Med: 47.99 Max: 2666.86
Current: 32.43
28.1
2666.86

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 3.86
ADK's 5-Year Yield-on-Cost % is ranked higher than
64% of the 311 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 2.23 vs. ADK: 3.86 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ADK' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.56  Med: 6.5 Max: 8.55
Current: 3.86
2.56
8.55
3-Year Average Share Buyback Ratio -7.60
ADK's 3-Year Average Share Buyback Ratio is ranked lower than
73% of the 130 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: -2.50 vs. ADK: -7.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ADK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -43  Med: -25.7 Max: -7.6
Current: -7.6
-43
-7.6

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 2.06
ADK's Price-to-Median-PS-Value is ranked lower than
93% of the 199 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 1.04 vs. ADK: 2.06 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ADK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 0.92 Max: 7.11
Current: 2.06
0.35
7.11
Earnings Yield (Greenblatt) % 4.91
ADK's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 334 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 4.98 vs. ADK: 4.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ADK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.6  Med: 2.1 Max: 6.6
Current: 4.91
0.6
6.6
Forward Rate of Return (Yacktman) % -21.62
ADK's Forward Rate of Return (Yacktman) % is ranked lower than
75% of the 119 Companies
in the Global Long-Term Care Facilities industry.

( Industry Median: 11.19 vs. ADK: -21.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ADK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -21.62  Med: -6.9 Max: 12.1
Current: -21.62
-21.62
12.1

More Statistics

Revenue (TTM) (Mil) $27.34
EPS (TTM) $ -0.74
Beta1.46
Short Percentage of Float1.79%
52-Week Range $1.02 - 2.60
Shares Outstanding (Mil)19.81
» More Articles for ADK

Headlines

Articles On GuruFocus.com
AdCare Health Systems Names Allan Rimland as Chief Executive Officer Apr 18 2017 
DIAGNOS Announces Operational Update of a Contract in India Valued at Up to $1.3M Jul 05 2016 
DIAGNOS Announces Major Strategic Alliance in Latin America for a Contract of $1.38 M USD Jun 08 2016 
DIAGNOS Announces Short Term Financing Jun 07 2016 
DIAGNOS Announces Changes to its Board of Directors May 20 2016 
DIAGNOS Announces an Update following Closing of Private Placement May 18 2016 
DIAGNOS Announces Closing of Private Placement May 03 2016 
DIAGNOS Announces Short Term Financing Apr 25 2016 
DIAGNOS Announces Private Placement Apr 07 2016 
DIAGNOS Announces Financing Update Feb 26 2016 

More From Other Websites
ETFs with exposure to AdCare Health Systems, Inc. : April 21, 2017 Apr 21 2017
AdCare Health Systems, Inc. :ADK-US: Earnings Analysis: Q4, 2016 By the Numbers : April 20, 2017 Apr 20 2017
AdCare Health Systems Names Allan Rimland as Chief Executive Officer Apr 18 2017
Park City Capital Calls on Adcare Health Systems, Inc. CEO Bill McBride to Resign due to Resume... Apr 04 2017
Edited Transcript of ADK earnings conference call or presentation 24-Mar-17 1:00pm GMT Apr 03 2017
AdCare Health posts 4Q profit Mar 24 2017
AdCare Health Systems Reports Fourth Quarter and Full-Year Financial 2016 Results Mar 24 2017
AdCare Schedules Conference Call to Discuss Fourth Quarter and Year End 2016 Financial Results Mar 08 2017
AdCare Health Systems, Inc. Declares Quarterly Dividend on Series A Cumulative Redeemable Preferred... Mar 03 2017
AdCare Signs Letter of Intent to Purchase Alabama Facility for $5.5 Million Feb 16 2017
AdCare Announces CMS Recertification of Oceanside Facility Feb 07 2017
AdCare Announces Results of Its Tender Offer for Any and Up to All of Its Outstanding 10%... Jan 10 2017
AdCare Announces Recertification of Jeffersonville Facility Dec 20 2016
AdCare Signs Letter of Intent to Purchase Tennessee Facility for $9 Million Dec 19 2016
ETFs with exposure to AdCare Health Systems, Inc. : December 16, 2016 Dec 16 2016
AdCare Completes HUD Refinancing of South Carolina Property Dec 15 2016
AdCare Commences Tender Offer for its 10% Convertible Subordinated Notes Due April 30, 2017 Dec 08 2016
AdCare Health Systems, Inc. :ADK-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016 Nov 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)